Announcements Trials
Browse Landscape

Phase

Phase 2/3 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1Classical hematology 1

Conditions

Myelodysplastic Syndromes 5Leukemia, Myeloid, Acute 5Leukemia, Myelomonocytic, Chronic 3Solid Tumor 1Melanoma 1Leukemia, Biphenotypic, Acute 1Leukemia 1Hematologic Diseases 1Cytopenia 1Anemia, Refractory, with Excess of Blasts 1

Interventions

pirtobrutinib 6Cyclophosphamide 6Mycophenolic Acid 5fludarabine phosphate 4fludarabine 4Rituximab 4Melphalan 4Azacitidine 4venetoclax 3ibrutinib 3Whole-Body Irradiation 3Tacrolimus 3Mesna 3Peripheral Blood Stem Cell Transplantation 2Patient Reported Outcome Measures 2Lenalidomide 2Cyclosporine 2Busulfan 2Brentuximab Vedotin 2Bone Marrow Transplantation 2Blood Specimen Collection 2Bendamustine Hydrochloride 2zanubrutinib 1ruxolitinib 1ponatinib 1pembrolizumab 1nilotinib 1idelalisib 1idecabtagene vicleucel 1cedazuridine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Hematologic Diseases × cedazuridine × 1 year × Clear all
NCT04256317 2026-04-30

A Multi-phase Study of ASTX030 (Azacitidine and Cedazuridine) in Myeloid Neoplasm Alone or in Combination With Venetoclax in AML (AZTOUND Study)

Taiho Oncology, Inc.

Phase 2/3 Recruiting
316 enrolled
Classical hematologyMyeloidOther hematologic neoplasm

Anemia, Refractory, with Excess of Blasts, Hematologic Diseases, Leukemia, Myelodysplastic Syndromes, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡